Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.59 |
| ▸ | CTSS | P25774 | 6/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193077 | 1.00 | CACNA1B (0.59) | CACNA1BCTSSCTSKKMT2ANPSR1 | |
| SCHEMBL12333298 | 0.91 | CACNA1B (0.57) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL10076795 | 0.90 | CACNA1B (0.70) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL3576709 | 0.90 | CACNA1B (0.56) | CACNA1BCTSSCTSKCTSLCTSB | |
| SCHEMBL375820 | 0.90 | CACNA1B (0.56) | CACNA1BCTSSCTSKKMT2ACTSL | |
| SCHEMBL5820678 | 0.90 | CTSS (0.57) | CACNA1BCTSSCTSKKMT2ACTSL | |
| SCHEMBL5820675 | 0.90 | CTSS (0.57) | CACNA1BCTSSCTSKKMT2ACTSL | |
| SCHEMBL376098 | 0.86 | CACNA1B (0.52) | CACNA1BCTSSCTSKACE | |
| SCHEMBL192655 | 0.86 | YAP1 (0.59) | CACNA1BACEITGB3ITGA2B | |
| SCHEMBL192656 | 0.86 | YAP1 (0.59) | CACNA1BACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4053116-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD Bioscience Inc. (KR) | 2022-09-07 | — | — | EP | disclosed |
| CN-114616229-A | Tricyclic compounds and pharmaceutical uses thereof | 镇斗生物科技股份公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-1877366-B1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2012-01-04 | — | — | EP | disclosed |
| EP-1877366-B1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-1877366-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TPH1, SLC6A4, TPH2 | CACNA1B 325/4885CTSS 688/4885CTSK 859/4885 |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | CACNA1B 2547/4885CTSS 901/4885CTSK 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.